July 8, 2008
Pulmo BioTech’s Subsidiary Completes Bio-Distribution Studies
Pulmo BioTech has announced that its subsidiary, PulmoScience has completed the bio-distribution studies on its DFH-12 product candidate for the PulmoBind technology of molecular imaging of the vascular system of the lungs.
The in- vivo studies have shown that the molecule is predominantly retained in the lungs 30 minutes after injection with only minor retention in the liver and heart.
Further bio-distribution studies have also shown that after 240 minutes the majority of the injected molecules have been eliminated through the kidneys and bladder.